Pneumococcal Vaccine Effectiveness and Disease Burden
Author Information
Author(s): King Laura M, Andrejko Kristin L, Kobayashi Miwako, Xing Wei, Cohen Adam L, Self Wesley H, Resser J Jackson, Whitney Cynthia G, Baughman Adrienne, Kio Mai, Grijalva Carlos G, Traenkner Jessica, Rouphael Nadine, Lewnard Joseph A
Primary Institution: Cold Spring Harbor Laboratory
Hypothesis
What are the proportions of pneumococcal diseases caused by serotypes targeted by existing and pipeline vaccines?
Conclusion
The study found that coverage and preventable burdens of pneumococcal diseases vary significantly among different vaccines.
Supporting Evidence
- PCV15, PCV20, PCV24, PCV25, and PCV31 serotypes account for varying percentages of pneumococcal acute otitis media cases in children.
- In adults, PCV15, PCV20, PCV21, PCV24, PCV25, and PCV31 serotypes account for significant percentages of non-bacteremic pneumonia cases.
- 42–85% of pediatric and 42–94% of adult IPD cases were due to PCV-targeted serotypes.
- PCV-preventable burdens include hundreds of thousands of outpatient-managed ARIs and thousands of pneumonia hospitalizations and IPD cases annually.
Takeaway
This study looks at how many cases of sickness caused by a germ called pneumococcus can be prevented by vaccines, showing that some vaccines work better than others.
Methodology
The study used Markov chain Monte Carlo approaches to estimate serotype distribution and disease burdens based on existing data.
Statistical Information
Confidence Interval
95% confidence interval: 15–17%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website